Key Points
- Ra Capital Management bought 6,387 more shares of Hemab Therapeutics on May 12 at an average price of $24.90, bringing its direct ownership to 6,372,170 shares.
- The filing shows continued aggressive buying by Ra Capital over multiple days, including a very large 2.675 million-share purchase on May 4 at $18.00 and several additional buys later in the week.
- Hemab Therapeutics shares opened at $28.37 on Friday, and Wall Street Zen recently upgraded the stock to a hold rating.
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) major shareholder Ra Capital Management, L.P. bought 6,387 shares of the company's stock in a transaction dated Tuesday, May 12th. The stock was acquired at an average price of $24.90 per share, for a total transaction of $159,036.30. Following the acquisition, the insider directly owned 6,372,170 shares in the company, valued at $158,667,033. This trade represents a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, May 11th, Ra Capital Management, L.P. bought 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.81 per share, for a total transaction of $989,149.89.
- On Friday, May 8th, Ra Capital Management, L.P. bought 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, for a total transaction of $37,045.34.
- On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
- On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00.
Hemab Therapeutics Price Performance
NASDAQ:COAG opened at $28.37 on Friday. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.00 and a 52 week high of $36.61.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Hemab Therapeutics to a "hold" rating in a report on Saturday, May 9th.
Check Out Our Latest Stock Analysis on Hemab Therapeutics
Hemab Therapeutics Company Profile
(
Get Free Report)
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
